An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors

Trial Profile

An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Anetumab ravtansine (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 15 Aug 2017 Planned End Date changed from 14 Oct 2017 to 31 Dec 2017.
    • 15 Aug 2017 Planned End Date changed from 14 Oct 2017 to 31 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top